Overview
- TickerEWTX on Nasdaq1
- IndustryPharmaceutical Preparations1
- HeadquartersBoulder, Colorado1
- Incorporated inDE2
- Business address1715 38Th St, Boulder, Co 803012
- Filer categoryLarge accelerated filer2
See how the biggest companies compare on our leaderboards
Our mission is to discover new medicines that improve the lives of people facing serious muscle disease.3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Research and development | $151.4M | $127.0M | $90.9M |
| General and administrative | $40.0M | $31.9M | $23.5M |
| Total operating expenses | $191.4M | $158.8M | $114.4M |
| Loss from operations | -$191.4M | -$158.8M | -$114.4M |
| Interest income | $23.6M | $25.0M | $14.2M |
| Total other income | $23.6M | $25.0M | $14.2M |
| Net loss | -$167.8M | -$133.8M | -$100.2M |
| Unrealized gain on available-for-sale securities | $257.0K | $321.0K | $1.5M |
| Total comprehensive loss | -$167.5M | -$133.5M | -$98.7M |
| Net loss per share, basic (in dollars per share) | -$1.63 | -$1.45 | -$1.57 |
| Net loss per share, diluted (in dollars per share) | -$1.63 | -$1.45 | -$1.57 |
| Weighted-average shares outstanding, basic (in shares) | 102.9M shares | 92.4M shares | 63.7M shares |
| Weighted-average shares outstanding, diluted (in shares) | 102.9M shares | 92.4M shares | 63.7M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 4 fiscal years (annual) or 4 quarters (quarterly), latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $61.1M | $41.7M | ||
| Marketable securities, available for sale | $469.0M | $428.5M | ||
| Prepaid expenses and other assets | $13.3M | $5.3M | ||
| Total current assets | $543.4M | $475.5M | ||
| Property and equipment, net | $7.8M | $9.5M | ||
| Operating lease right-of-use asset | $1.4M | $1.6M | ||
| Other non-current assets | $262.0K | |||
| Total assets | $552.6M | $486.8M | ||
| Accounts payable | $6.0M | $5.6M | ||
| Accrued compensation | $12.4M | $10.1M | ||
| Accrued other expenses | $7.9M | $7.2M | ||
| Operating lease liability, current portion | $1.0M | $996.0K | ||
| Total current liabilities | $27.4M | $23.9M | ||
| Operating lease liability, net of current portion | $3.0M | $3.7M | ||
| Total liabilities | $30.3M | $27.6M | ||
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 106,249,579 shares and 94,838,466 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $10.0K | $9.0K | ||
| Additional paid-in capital | $1.1B | $837.4M | ||
| Accumulated other comprehensive income | $677.0K | $420.0K | ||
| Accumulated deficit | -$546.4M | -$378.6M | ||
| Total stockholders' equity | $522.3M | $459.2M | $318.8M | $346.7M |
| Total liabilities and stockholders' equity | $552.6M | $486.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 1.0B shares | 1.0B shares | ||
| Common stock, shares issued | 106.2M shares | 94.8M shares | ||
| Common stock, shares outstanding | 106.2M shares | 94.8M shares |
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Cash and cash equivalents | $61.1M | $41.7M | ||
| Marketable securities, available for sale | $469.0M | $428.5M | ||
| Prepaid expenses and other assets | $13.3M | $5.3M | ||
| Total current assets | $543.4M | $475.5M | ||
| Property and equipment, net | $7.8M | $9.5M | ||
| Operating lease right-of-use asset | $1.4M | $1.6M | ||
| Other non-current assets | $262.0K | |||
| Total assets | $552.6M | $486.8M | ||
| Accounts payable | $6.0M | $5.6M | ||
| Accrued compensation | $12.4M | $10.1M | ||
| Accrued other expenses | $7.9M | $7.2M | ||
| Operating lease liability, current portion | $1.0M | $996.0K | ||
| Total current liabilities | $27.4M | $23.9M | ||
| Operating lease liability, net of current portion | $3.0M | $3.7M | ||
| Total liabilities | $30.3M | $27.6M | ||
| Common stock, $.0001 par value per share; 1,000,000,000 shares authorized as of December 31, 2025 and December 31, 2024; 106,249,579 shares and 94,838,466 shares issued and outstanding as of December 31, 2025 and December 31, 2024, respectively | $10.0K | $9.0K | ||
| Additional paid-in capital | $1.1B | $837.4M | ||
| Accumulated other comprehensive income | $677.0K | $420.0K | ||
| Accumulated deficit | -$546.4M | -$378.6M | ||
| Total stockholders' equity | $522.3M | $459.2M | $318.8M | $346.7M |
| Total liabilities and stockholders' equity | $552.6M | $486.8M | ||
| Preferred stock, par value | $0.00 | $0.00 | ||
| Preferred stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | ||
| Preferred stock, shares issued | 0 shares | 0 shares | ||
| Preferred stock, shares outstanding | 0 shares | 0 shares | ||
| Common stock, par value | $0.00 | $0.00 | ||
| Common stock, shares authorized | 1.0B shares | 1.0B shares | ||
| Common stock, shares issued | 106.2M shares | 94.8M shares | ||
| Common stock, shares outstanding | 106.2M shares | 94.8M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 3 fiscal years, latest first.7
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Net loss | -$167.8M | -$133.8M | -$100.2M |
| Depreciation | $2.1M | $2.1M | $1.6M |
| Stock-based compensation | $34.8M | $24.7M | $17.6M |
| Accretion of discount on marketable securities, net | -$7.7M | -$12.5M | -$9.5M |
| Amortization of right-of-use asset | $182.0K | $221.0K | $181.0K |
| Prepaid expenses and other assets | -$8.0M | $3.3M | -$3.6M |
| Accounts payable | $272.0K | $1.7M | -$92.0K |
| Accrued compensation | $2.4M | $4.4M | $1.7M |
| Accrued other expenses and other liabilities | $691.0K | $1.2M | $526.0K |
| Lease liability | -$748.0K | -$220.0K | -$104.0K |
| Net cash used in operating activities | -$143.8M | -$109.0M | -$91.9M |
| Purchases of marketable securities | -$527.2M | -$477.1M | -$255.9M |
| Sales of marketable securities | $67.4M | $15.8M | $20.1M |
| Maturities of marketable securities | $427.3M | $277.9M | $344.4M |
| Purchases of property and equipment | -$256.0K | -$1.3M | -$5.7M |
| Net cash (used in) provided by investing activities | -$32.8M | -$184.7M | $102.9M |
| Proceeds from issuance of common stock, net of offering costs | $187.4M | $239.1M | $52.6M |
| Exercise of stock options | $7.8M | $9.5M | $117.0K |
| Payment of deferred offering costs | -$262.0K | -$165.0K | |
| Proceeds from Employee Stock Purchase Plan | $923.0K | $888.0K | $596.0K |
| Net cash provided by financing activities | $196.1M | $249.3M | $53.2M |
| Net change in cash and cash equivalents | $19.5M | -$44.4M | $64.1M |
| Right-of-use asset obtained in exchange for new operating lease liability, net of tenant improvement receivable | $1.1M | ||
| Property and equipment purchases included in accounts payable and accrued other expenses | $199.0K | $44.0K | $227.0K |
No quarter-by-quarter statement was filed.
Corporate structure
Edgewise Therapeutics, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of Edgewise Therapeutics, Inc.
- BAKER BROS. ADVISORS LP Filed SCHEDULE 13G/A on Edgewise Therapeutics, Inc., latest Aug 14, 2026 (3 filings since Nov 14, 2024)
- Paradigm Biocapital Advisors LP Filed SCHEDULE 13G/A on Edgewise Therapeutics, Inc., latest Aug 14, 2026 (3 filings since Feb 3, 2025)
- RA CAPITAL MANAGEMENT, L.P. Filed SCHEDULE 13G/A on Edgewise Therapeutics, Inc., latest Aug 14, 2026 (5 filings since Feb 14, 2022)
- FMR LLC Filed SCHEDULE 13G on Edgewise Therapeutics, Inc., latest Aug 6, 2026 (7 filings since Feb 9, 2022)
- Janus Henderson Group Ltd. Filed SCHEDULE 13G on Edgewise Therapeutics, Inc., latest May 15, 2026 (5 filings since Feb 14, 2025)
- Novo Holdings A/S Filed SCHEDULE 13D/A on Edgewise Therapeutics, Inc., latest Apr 27, 2026 (6 filings since Sep 16, 2022)
- PERCEPTIVE ADVISORS LLC Filed SCHEDULE 13G/A on Edgewise Therapeutics, Inc., latest Aug 14, 2025 (3 filings since Feb 21, 2025)
- BlackRock Filed SCHEDULE 13G/A on Edgewise Therapeutics, Inc., latest Jul 17, 2025 (5 filings since Feb 2, 2024)
- ORBIMED ADVISORS LLC Filed SCHEDULE 13D/A on Edgewise Therapeutics, Inc., latest May 12, 2025 (4 filings since Sep 16, 2022)
- EcoR1 Capital, LLC Filed SC 13G/A on Edgewise Therapeutics, Inc., latest Nov 14, 2024 (2 filings since Sep 26, 2022)
- James E. Flynn Filed SC 13G/A on Edgewise Therapeutics, Inc., latest Nov 14, 2024 (3 filings since Feb 10, 2023)
- VIKING GLOBAL INVESTORS LP Filed SC 13G/A on Edgewise Therapeutics, Inc., latest Nov 14, 2024 (4 filings since Feb 14, 2022)
- Edgewise Therapeutics, Inc. Boulder, Colorado
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What Edgewise Therapeutics, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Property and equipment
| Item | Latest | A year before | Change |
|---|---|---|---|
| Property and equipment, before depreciation | $14.6M7 Dec 31, 2025 | $14.2M7 Dec 31, 2024 | +2.9% |
| Accumulated depreciation | $6.8M7 Dec 31, 2025 | $4.7M7 Dec 31, 2024 | +44.5% |
| Property and equipment, net | $7.8M7 Dec 31, 2025 | $9.5M7 Dec 31, 2024 | −17.6% |
| Operating-lease assets (leased space) | $1.4M7 Dec 31, 2025 | $1.6M7 Dec 31, 2024 | −11.6% |
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $61.1M7 Dec 31, 2025 | $41.7M7 Dec 31, 2024 | +46.8% |
Properties, in its own words
Our headquarters are based in Boulder, Colorado where the company entered into a lease agreement for approximately 18,614 square feet of office and laboratory space in January 2022. The lease includes escalating rent payments and an 8.2 year term. In February 2023, we signed an amendment to this lease to occupy additional 9,624 square feet of space. The future minimum lease payments are disclosed in Note 5 to our financial statements appearing in this Annual Report. We believe our facilities are adequate and suitable for our current needs, and that suitable additional or alternative space will be available to accommodate our operations if needed.
Item 2 of the 10-K filed Feb 26, 2026.3
Leadership
Who has led Edgewise Therapeutics, Inc., and when. Pick a name to see everywhere that person has worked.
Chief executive
President
Chief financial officer
2025
- Chief executive officerKevin Koch Mar 25, 2021 to now11
- PresidentKevin Koch Mar 25, 2021 to now11
- Chief financial officerMichael Nofi Nov 13, 2025 to now12
Board members and other officers (15)
- Chief Development OfficerRobert Blaustein Jan 23, 2025 to now13
- Chief Development OfficerMarc Semigran Dec 22, 2022 to Dec 27, 202414
- Chief Scientific OfficerAlan J. Russell Mar 25, 2021 to now15
- Chief Business OfficerBehrad Derakhshan Mar 25, 2021 to now16
- CMOJoanne M. Donovan May 4, 2021 to now17
- Board memberChristopher Nathan Martin Nov 24, 2025 to now18
- Board memberArlene Morris May 7, 2024 to now19
- Board memberAlan J. Russell Mar 25, 2021 to now15
- Board memberBadreddin Edris Mar 25, 2021 to now20
- Board memberJonathan D. Root Mar 25, 2021 to now21
- Board memberKenneth Ph.d. Harrison Mar 25, 2021 to Mar 25, 202122
- Board memberKevin Koch Mar 25, 2021 to now11
- Board memberLaura Brege Mar 25, 2021 to now23
- Board memberPeter A. Thompson Mar 25, 2021 to now24
- General counselJohn R. Moore Mar 25, 2021 to now25
Timeline
- Aug 6, 20268-K Results of operations26
- Jul 16, 20268-K Financial statements and exhibits27
- Jul 13, 20268-K Completed an acquisition or sale; Regulation FD disclosure28
- Jun 5, 20268-K Shareholder vote29
- Jun 1, 20268-K Entered a material agreement30
- May 7, 20268-K Results of operations31
- Feb 26, 20268-K Results of operations32
- Nov 20, 20258-K Executive or director change33
- Nov 10, 20258-K Executive or director change; Regulation FD disclosure34
- Nov 6, 20258-K Results of operations35
- Aug 7, 20258-K Results of operations36
- Jun 26, 20258-K Regulation FD disclosure; Other events37
- Mar 25, 2021New chief executive Kevin Koch becomes CEO11
Calendar
Coming up
- Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.39) a share, on Nov 6, 2025.38
When it reported results
- Aug 6, 2026Reported quarterly or annual results26
- May 7, 2026Reported quarterly or annual results31
- Feb 26, 2026Reported quarterly or annual results32
- Nov 6, 2025Reported quarterly or annual results35
- Aug 7, 2025Reported quarterly or annual results36
- May 8, 2025Reported quarterly or annual results39
- Mar 3, 2025Reported quarterly or annual results40
- Nov 7, 2024Reported quarterly or annual results41
Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar
Filings
357 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 47 major events, 170 insider forms, 58 large holders, 62 other. The latest 20:
- Oct 2, 20264 PRIMARY DOCUMENT EDGAR
- Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
- Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
- Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
- Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
- Aug 17, 20264/A PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 20264 PRIMARY DOCUMENT EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 14, 2026SCHEDULE 13G/A EDGAR
- Aug 13, 2026144 EDGAR
- Aug 6, 20268-K EDGAR
- Aug 6, 202610-Q EDGAR
- Aug 6, 2026SCHEDULE 13G EDGAR
- Jul 17, 20264 PRIMARY DOCUMENT EDGAR
The 357 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Insider trades
113 open-market trades by officers, directors and large owners since October 2021: 11 buys and 102 sales. Grants, option exercises and gifts are left out.
| Date | Who | Trade | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| Aug 13, 2026 | Donovan Joanne M.CMO | Sale | 2,919 | $43.41 | $126.7K | Form 4 |
| Aug 12, 2026 | Russell Alan JChief Scientific Officer | Sale | 5,901 | $43.73 | $258.1K | Form 4 |
| Aug 12, 2026 | Derakhshan BehradChief Business Officer | Sale | 5,100 | $43.81 | $223.4K | Form 4 |
| Aug 12, 2026 | Donovan Joanne M.CMO | Sale | 6,522 | $43.85 | $286.0K | Form 4 |
| Aug 12, 2026 | MOORE JOHN RGeneral Counsel | Sale | 5,016 | $43.83 | $219.8K | Form 4 |
| Aug 12, 2026 | KOCH KEVINPresident and CEO | Sale | 17,971 | $43.68 | $785.0K | Form 4 |
| Jul 1, 2026 | Russell Alan JChief Scientific Officer | Sale | 200,000 | $39.41 | $7.9M | Form 4 |
| May 5, 2026 | Donovan Joanne M.CMO | Sale | 50,000 | $38.57 | $1.9M | Form 4 |
| May 4, 2026 | Donovan Joanne M.CMO | Sale | 5,230 | $31.29 | $163.6K | Form 4 |
| Apr 1, 2026 | Donovan Joanne M.CMO | Sale | 28,662 | $32.31 | $926.1K | Form 4 |
| Mar 31, 2026 | Donovan Joanne M.CMO | Sale | 21,338 | $32.12 | $685.4K | Form 4 |
| Mar 27, 2026 | Donovan Joanne M.CMO | Sale | 16,358 | $30.98 | $506.8K | Form 4 |
| Jan 21, 2026 | Edris BadreddinDirector | Sale | 115,471 | $29.44 | $3.4M | Form 4 |
| Nov 12, 2025 | Russell Alan JChief Scientific Officer | Sale | 100,000 | $21.12 | $2.1M | Form 4 |
| Nov 11, 2025 | Fox Jonathan CDirector | Buy | 10,700 | $18.64 | $199.4K | Form 4 |
| Aug 26, 2025 | Russell Alan JChief Scientific Officer | Sale | 100,000 | $14.60 | $1.5M | Form 4 |
| Aug 12, 2025 | MOORE JOHN RGeneral Counsel | Sale | 2,098 | $13.39 | $28.1K | Form 4 |
| Aug 12, 2025 | Derakhshan BehradChief Business Officer | Sale | 2,491 | $13.39 | $33.4K | Form 4 |
| Aug 12, 2025 | Carruthers R MichaelChief Financial Officer | Sale | 1,428 | $13.39 | $19.1K | Form 4 |
| Aug 12, 2025 | Russell Alan JChief Scientific Officer | Sale | 1,907 | $13.39 | $25.5K | Form 4 |
All 113 trades can be filtered by person here when JavaScript is on.
From Forms 4 filed with the SEC.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- BAKER BROS. ADVISORS LPSCHEDULE 13G/A, 3 filings Nov 14, 2024 to Aug 14, 202642
- Paradigm Biocapital Advisors LPSCHEDULE 13G/A, 3 filings Feb 3, 2025 to Aug 14, 202643
- RA CAPITAL MANAGEMENT, L.P.SCHEDULE 13G/A, 5 filings Feb 14, 2022 to Aug 14, 202644
- FMR LLCSCHEDULE 13G, 7 filings Feb 9, 2022 to Aug 6, 202645
- Janus Henderson Group Ltd.SCHEDULE 13G, 5 filings Feb 14, 2025 to May 15, 202646
- Novo Holdings A/SSCHEDULE 13D/A, 6 filings Sep 16, 2022 to Apr 27, 202647
- PERCEPTIVE ADVISORS LLCSCHEDULE 13G/A, 3 filings Feb 21, 2025 to Aug 14, 202548
- BlackRockSCHEDULE 13G/A, 5 filings Feb 2, 2024 to Jul 17, 202549
- ORBIMED ADVISORS LLCSCHEDULE 13D/A, 4 filings Sep 16, 2022 to May 12, 202550
- EcoR1 Capital, LLCSC 13G/A, 2 filings Sep 26, 2022 to Nov 14, 202451
- James E. FlynnSC 13G/A, 3 filings Feb 10, 2023 to Nov 14, 202452
- VIKING GLOBAL INVESTORS LPSC 13G/A, 4 filings Feb 14, 2022 to Nov 14, 202453
- Deep Track Capital, LPSC 13G/A, 2 filings Sep 23, 2022 to Feb 14, 202454
- CITADEL ADVISORS LLCSC 13G/A, 3 filings Jan 13, 2022 to Feb 14, 202355
- Cormorant Global Healthcare Master Fund, LPSC 13G/A, 2 filings Feb 14, 2022 to Feb 14, 202356
- U.S. Venture Partners XI, L.P.SC 13D/A, 1 filing Feb 1, 202357
Executive pay
What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.
| Year | Executive | Age | Salary | Total pay |
|---|---|---|---|---|
| 2025 | Kevin KochPh.D. | $670.0K | $7.4M58 | |
| 2025 | Former Chief Development Officer | $525.0K | $4.6M58 | |
| 2025 | Chief Financial Officer | $67.8K | $4.3M58 | |
| 2025 | Behrad DerakhshanPh.D. | $520.0K | $2.9M58 | |
| 2025 | Joanne M. DonovanM.D., Ph.D. | $530.4K | $2.8M58 | |
| 2025 | Co-Founder and | $499.6K | $2.7M58 | |
| 2025 | Former Chief Financial Officer | $465.7K | $2.6M58 | |
| 2024 | President and | $618.7K | $7.6M58 | |
| 2024 | Chief Medical Officer | $507.5K | $2.9M58 | |
| 2024 | Chief Operating Officer | $478.4K | $2.9M58 | |
| 2023 | Chief Executive Officer | $594.9K | $4.0M58 | |
| 2023 | Chief Operating Officer | $446.7K | $1.8M58 | |
| 2023 | Chief Medical Officer | $488.0K | $1.7M58 |
Held by these funds
The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.
| Fund | Shares | Value | Share of the fund | Change |
|---|---|---|---|---|
| Orbimed Advisors LLC | 15,518,492 | $630.5M | 12.0% | No change |
| Paradigm Biocapital Advisors LP | 10,215,455 | $415.1M | 7.8% | +2,850,417 |
| Ra Capital Management, L.P. | 8,392,730 | $341.0M | 3.0% | −2,035,707 |
| BlackRock, Inc. | 6,606,336 | $268.4M | 0.0% | +133,345 |
| Jupiter Topco LLC | 6,075,331 | $246.9M | 0.1% | New |
| Fmr LLC | 5,489,135 | $223.0M | 0.0% | +4,472,083 |
| Novo Holdings A/s | 5,350,000 | $217.4M | 12.6% | No change |
| Driehaus Capital Management LLC | 4,728,623 | $192.1M | 1.1% | +250,681 |
| Perceptive Advisors LLC | 4,373,974 | $177.7M | 2.8% | −50,000 |
| Vanguard Capital Management LLC | 3,860,670 | $156.9M | 0.0% | +72,509 |
| Baker Bros. Advisors LP | 3,701,719 | $150.4M | 0.8% | −2,874,221 |
| Siren, L.L.C. | 3,184,629 | $129.4M | 2.6% | −1,245,634 |
| Cormorant Asset Management, LP | 2,510,000 | $102.0M | 5.2% | −750,000 |
| Geode Capital Management, LLC | 2,174,051 | $88.3M | 0.0% | +384,232 |
| Integral Health Asset Management, LLC | 2,000,000 | $81.3M | 3.3% | +400,000 |
| Braidwell LP | 1,996,965 | $81.1M | 3.1% | −350,618 |
| Morgan Stanley | 1,948,597 | $79.2M | 0.0% | −297,431 |
| State Street Corp | 1,827,927 | $74.3M | 0.0% | +111,104 |
| Alliancebernstein L.P. | 2,119,024 | $66.7M | 0.0% | +396,855 |
| Mpm Bioimpact LLC | 1,620,780 | $65.9M | 4.0% | −39,916 |
| Bank Of America Corp /de/ | 1,558,260 | $63.3M | 0.0% | +230,900 |
| Qube Research & Technologies Ltd | 1,252,507 | $50.9M | 0.1% | +426,597 |
| Dimensional Fund Advisors LP | 1,139,726 | $46.3M | 0.0% | −79,991 |
| American Century Companies Inc | 1,127,078 | $45.8M | 0.0% | −20,098 |
| First Light Asset Management, LLC | 1,095,171 | $44.5M | 2.7% | +93,325 |
13F reports cover disclosed long positions in U.S. stocks only.
SEC filer profile
How Edgewise Therapeutics, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGAREdgewise Therapeutics, Inc.1
- CIK0001710072
- Employer ID (EIN)82-17255863
- Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2834 Pharmaceutical Preparations1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address1715 38Th St, Boulder, CO 803011
- Phone720-262-70021
- Shares outstanding108,604,129 as of Jul 31, 20269
- Public float$1.2B as of Jun 30, 20253
- AuditorKPMG LLP, Denver, Colorado PCAOB ID 185; it also attests to the company’s internal control over financial reporting3
- On EDGAR sinceSep 26, 20191
- Filings419 in all: 4 (174), 8-K (49), 144 (28), 3 (22), SC 13G/A (20), 10-Q (17), SC 13G (14), SCHEDULE 13G/A (12)1
All 38 form types
SC 13D/A (9), DEFA14A (7), S-8 (7), 424B5 (6), 10-K (5), 4/A (5), DEF 14A (5), SCHEDULE 13G (5), CORRESP (4), SC 13D (3), ARS (2), D (2), DRS/A (2), EFFECT (2), S-1/A (2), SCHEDULE 13D/A (2), UPLOAD (2), 424B3 (1), 424B4 (1), 8-A12B (1), 8-K/A (1), CERT (1), DRS (1), DRSLTR (1), PRE 14A (1), S-1 (1), S-1MEF (1), S-3 (1), S-3ASR (1), S-3MEF (1)
- Latest filingsAnnual report (10-K) Feb 26, 2026
Quarterly report (10-Q) Aug 6, 2026
Proxy statement (DEF 14A) Apr 23, 2026
Latest 8-K (8-K) Aug 6, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| Common stock, par value $0.0001 per share | EWTX | Nasdaq Global Select Market |
From the cover page of the 10-K filed Feb 26, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
The risks Edgewise Therapeutics, Inc. names in Item 1A of its 10-K filed Feb 26, 2026: 76 risks under these headings, as written.3
- Risks Related to Our Financial Position, Need for Additional Capital and Limited Operating History
- Risks Related to the Discovery, Development and Commercialization of Our Product Candidates
- Risks Related to Regulatory Approval and Other Legal Compliance Matters
- Risks Related to Employee Matters, Managing Our Growth and Other Risks Related to Our Business
- Risks Related to Our Intellectual Property
- Risks Related to Our Dependence on Third Parties
- We have a limited operating history and while we are moving toward becoming a commercial-ready biopharmaceutical company, some of our product candidates are early in development and we have no products approved for commercial sale, which may make it difficult for you to evaluate our current business and likelihood of success and future viability.
- We have not generated any revenue to date, have incurred significant net losses since our inception, and expect to continue to incur significant net losses for the foreseeable future.
- Our ability to generate revenue and achieve profitability depends significantly on our ability to achieve several objectives relating to the discovery, development and commercialization of our product candidates, if approved.
- We will require substantial additional capital to finance our operations. If we are unable to raise such capital when needed, or on acceptable terms, we may be forced to delay, reduce and/or eliminate one or more of our research and drug development programs or future commercialization efforts.
- Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.
- Our ability to utilize our net operating loss carryforwards and certain other tax attributes to offset future taxable income may be limited.
The other 67 risks
- Changes in tax laws could have a material adverse effect on our business, cash flow, results of operations or financial conditions.
- Market conditions and changing circumstances, some of which may be beyond our control, could impair our ability to access our existing cash, cash equivalents and investments and to timely pay key vendors and others.
- Our operations and financial results could be adversely impacted by public health pandemics, such as COVID-19 and other related outbreaks in the United States and the rest of the world.
- We are substantially dependent on the success of our lead product candidates, sevasemten and EDG-7500. If we are unable to complete further development of, obtain approval for and commercialize sevasemten or EDG-7500 for one or more indications in a timely manner, our business will be harmed.
- In addition to sevasemten and EDG-7500, our prospects depend in part upon developing and commercializing EDG-15400 and product candidates from our EDG-003 cardiometabolic discovery program and discovering, developing and commercializing product candidates in future programs, which may fail or suffer delays that adversely affect their commercial viability.
- Clinical drug development involves a lengthy and expensive process with an uncertain outcome. The clinical trials of our product candidates may not demonstrate safety and efficacy to the satisfaction of the FDA, EMA or other comparable foreign regulatory authorities or otherwise produce positive results and the results of preclinical studies and early clinical trials may not be predictive of future results. We may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
- Our product candidates may cause serious adverse events, toxicities or other undesirable side effects when used alone or in combination with other approved products or investigational new drugs that may result in a safety profile that could prevent regulatory approval, prevent market acceptance, limit their commercial potential or result in significant negative consequences.
- The outcome of preclinical testing and early clinical trials may not be predictive of the success of later clinical trials, and the results of our clinical trials may not satisfy the requirements of the FDA, EMA or other comparable foreign regulatory authorities.
- If we experience delays or difficulties in the enrollment and/or maintenance of patients in clinical trials, our regulatory submissions or receipt of necessary marketing approvals could be delayed or prevented.
- We have limited resources and are currently focusing the majority of our efforts on developing sevasemten and EDG-7500 for particular indications. As a result, we may fail to capitalize on other indications or product candidates that may ultimately have proven to be more profitable.
- We face significant competition and if our competitors develop and market technologies or products more rapidly than we do or that are more effective, safer or less expensive than the products we develop, our commercial opportunities will be negatively impacted.
- Interim, topline and preliminary data from our clinical trials that we announce or publish may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.
- We may not be successful in our efforts to develop a proprietary drug discovery platform to build a pipeline of product candidates.
- We may develop sevasemten and potentially other programs in combination with other therapies, which would expose us to additional risks.
- The manufacture of drugs is complex, and our third-party manufacturers may encounter difficulties in production. If any of our third-party manufacturers encounter such difficulties, our ability to provide adequate supply of our product candidates for clinical trials or our products for patients, if approved, could be delayed or prevented.
- Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
- Our product candidates may not achieve adequate market acceptance among physicians, patients, healthcare payors and others in the medical community necessary for commercial success.
- The patient population suffering from Duchenne, Becker and Limb-girdle muscular dystrophy (LGMD) is small and has not been established with precision. If the actual number of patients is smaller than we estimate, our revenue and ability to achieve profitability may be adversely affected. Because the target patient populations of our programs are small and the addressable patient population may be even smaller, we must be able to successfully identify patients and capture a significant market share to achieve profitability and growth.
- We may not be successful in augmenting our product pipeline through acquisitions and in-licenses.
- Any product candidates we develop may become subject to unfavorable third-party coverage and reimbursement practices, as well as pricing regulations.
- Our business entails a significant risk of product liability and if we are unable to obtain sufficient insurance coverage, such inability could have an adverse effect on our business and financial condition. If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our products.
- The regulatory approval processes of the FDA, EMA and other comparable foreign regulatory authorities are lengthy, time consuming and inherently unpredictable. If we are ultimately unable to obtain regulatory approval of our product candidates, we will be unable to generate product revenue and our business will be substantially harmed.
- The FDA, EMA and other comparable foreign regulatory authorities may not accept data from trials conducted in locations outside of their jurisdiction.
- Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
- The regulatory approval processes for product candidates that target rare diseases, including Duchenne, Becker and LGMD are uncertain.
- Even if our product candidates receive regulatory approval, they will be subject to significant post-marketing regulatory requirements and oversight.
- We may not be able to obtain orphan drug designation or obtain or maintain orphan drug exclusivity for our product candidates and, even if we do, that exclusivity may not prevent the FDA, EMA or other comparable foreign regulatory authorities, from approving competing products.
- We may face difficulties from changes to current regulations and future legislation.
- Inadequate funding for and other disruptions at the FDA, the SEC and other government agencies, including government shutdowns, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
- Our employees, independent contractors, consultants, commercial collaborators, principal investigators, CROs, suppliers and vendors may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements.
- If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on our business.
- Our business activities may be subject to the U.S. Foreign Corrupt Practices Act and similar anti-bribery and anti-corruption laws of other countries in which we operate, as well as other trade laws, including U.S. and certain foreign export and import controls, trade sanctions, and foreign investment and data export laws and regulations. Compliance with these legal requirements could limit our ability to compete in foreign markets and subject us to liability if we violate them.
- Our success is highly dependent on our ability to attract and retain highly skilled executive officers and employees.
- If we are unable to establish sales or marketing capabilities or enter into agreements with third parties to sell or market our product candidates, we may not be able to successfully sell or market our product candidates that obtain regulatory approval.
- In order to successfully implement our plans and strategies, we will need to grow the size of our organization, and we may experience difficulties in managing this growth.
- Our computer systems, or those of any of our CROs, manufacturers, other contractors, consultants, service providers, or potential future collaborators, may fail or suffer security or data privacy breaches or incidents or other unauthorized or improper access to, use of, or destruction of our proprietary or confidential data, employee data, or personal data, which could result in additional costs, loss of revenue, significant liabilities, harm to our brand and material disruption of our operations.
- Our operations are vulnerable to interruption by fire, earthquakes, power loss, telecommunications failure, terrorist activity, pandemics and other events beyond our control, which could harm our business.
- Our business may become subject to economic, political, regulatory and other risks associated with international operations directly or indirectly. A variety of risks associated with marketing our product candidates internationally could materially adversely affect our business.
- Inflation in the global economy could negatively impact our business and results of operations.
- Our success depends on our ability to protect our intellectual property and our proprietary technologies.
- If the scope of any patent protection we obtain is not sufficiently broad, or if we lose any of our patent protection, our ability to prevent our competitors from commercializing similar or identical product candidates would be adversely affected.
- Intellectual property rights do not necessarily address all potential threats to our competitive advantage.
- Our commercial success depends significantly on our ability to operate without infringing the patents and other proprietary rights of third parties. Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts.
- We may not be successful in obtaining or maintaining necessary rights to our product candidates through acquisitions and in-licenses.
- We may be involved in lawsuits to protect or enforce our patents or any licensor’s patents, which could be expensive, time consuming and unsuccessful. Further, our issued patents or any licensor’s patents could be found invalid or unenforceable if challenged in court.
- Intellectual property litigation may lead to unfavorable publicity that harms our reputation and causes the market price of our common shares to decline.
- Derivation proceedings may be necessary to determine priority of inventions, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party.
- Changes in U.S. patent law, or laws in other countries, could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.
- We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.
- Patent terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time.
- If we do not obtain patent term extension for our product candidates, our business may be materially harmed.
- We may not be able to protect our intellectual property rights throughout the world.
- Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by regulations and governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.
- If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.
- If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
- We may be subject to claims that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets.
- We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers.
- Our rights to develop and commercialize our technology and product candidates may be subject, in part, to the terms and conditions of licenses granted to us by others.
- If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with any licensors, we could lose license rights that are important to our business.
- The patent protection and patent prosecution for some of our product candidates may be dependent on third parties.
- Intellectual property discovered through government funded programs may be subject to federal regulations such as “march-in” rights, certain reporting requirements and a preference for U.S.-based companies. Compliance with such regulations may limit our exclusive rights and limit our ability to contract with non-U.S. manufacturers.
- We rely, and expect to continue to rely, on third parties to conduct our clinical trials and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials, research and studies, which may harm our business.
- Our reliance on third parties may require us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed.
- If we engage in future acquisitions or strategic partnerships, this may increase our capital requirements, dilute our stockholders, cause us to incur debt or assume contingent liabilities, and subject us to other risks.
- If we decide to establish collaborations, but are not able to establish those collaborations on commercially reasonable terms, we may have to alter our development and commercialization plans.
- We may enter into collaborations with third parties for the development and commercialization of product candidates. If those collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.
- Risks Related to the Securities Markets and Ownership of Our Common Stock
- An active, liquid and orderly trading market may not continue to be developed or sustained for our common stock and as a result it may be difficult for you to sell your shares of our common stock.
Legal proceedings
From time to time, we may be involved in various claims and legal proceedings relating to claims arising out of our operations. We are not currently a party to any material legal proceedings. The outcome of litigation cannot be predicted with certainty and some lawsuits, claims or proceedings may be disposed of unfavorably to us, which could materially affect our financial condition or results of operations.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11SEC EDGARKevin Koch, Chief executive officer
- 12
- 13
- 14
- 15
- 16
- 17SEC EDGARJoanne M. Donovan, CMO
- 18
- 19SEC EDGARArlene Morris, Board member
- 20SEC EDGARBadreddin Edris, Board member
- 21SEC EDGARJonathan D. Root, Board member
- 22SEC EDGARKenneth Ph.d. Harrison, Board member
- 23SEC EDGARLaura Brege, Board member
- 24SEC EDGARPeter A. Thompson, Board member
- 25SEC EDGARJohn R. Moore, General counsel
- 26SEC EDGARResults of operations
- 27SEC EDGARFinancial statements and exhibits
- 28
- 29SEC EDGARShareholder vote
- 30SEC EDGAREntered a material agreement
- 31SEC EDGARResults of operations
- 32SEC EDGARResults of operations
- 33SEC EDGARExecutive or director change
- 34
- 35SEC EDGARResults of operations
- 36SEC EDGARResults of operations
- 37
- 38NasdaqNasdaq calendar
- 39
- 40
- 41
- 42
- 43
- 44
- 45
- 46
- 47
- 48
- 49
- 50
- 51
- 52
- 53
- 54
- 55
- 56
- 57
- 58